News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cancer Genetics, Inc. Delays IPO to Avoid Faceoff with Facebook



5/21/2012 6:56:48 AM

Cancer Genetics (CGIX) operates in a completely different space than Facebook (FB), and while other companies are postponing their IPOs or withdrawing them all together, this name is still looking to start trading this week. It's possible that underwriters think because the offering is so small, there will still be plenty of available capital to participate in the IPO. Cancer Genetics is pricing 4 million shares in a range of $11.00 to $13.00. It hopes to raise $48 million, giving the company a total market cap of $111.9 million. The deal is underwritten by William Blair & Company, Baird, Needham & Company, and First Analysis Securities.

Read at Seeking Alpha
Read at North Jersey
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES